コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ted to be a novel proinflammatory ligand for Toll-like receptor 9.
2 ly endocytic compartments in pDCs to trigger Toll-like receptor 9.
3 ferently directed to the B-cell receptor and Toll-like receptor 9.
4 recognition threshold for the activation of Toll-like receptor 9.
5 ction and organ damage through activation of Toll-like receptor 9.
6 s modified by the expression of its receptor toll-like receptor-9.
8 ort isoform predominates in CD27(+) B cells, toll-like receptor 9-activated peripheral B cells, and s
9 outcome of severe sepsis is associated with toll-like receptor 9 activation in neutrophils, which tr
10 e bone marrow both in vitro and in vivo upon Toll-like receptor-9 activation and whose adoptive trans
13 treatment with antigen in the presence of a Toll-like receptor 9 agonist can suppress TH2-mediated r
14 particle with CpG-motif G10 inside), a novel Toll-like receptor 9 agonist packaged into virus-like pa
15 A (siRNA) delivery platform by conjugating a Toll-like receptor 9 agonist with siRNA that efficiently
16 ed the IgG response by coadministration of a Toll-like receptor 9 agonist, among other adjuvants exam
17 wed that stimulation of innate immunity with Toll-like receptor 9 agonist, class B CpG (cytosine-phos
18 missible gastroenteritis virus (TGEV) or the Toll-like receptor 9 agonist, oligodeoxynucleotide (ODN)
19 f CpG oligodeoxynucleotide 2216 (ODN2216), a Toll-like receptor 9 agonist, was investigated with mono
20 s formulated with the adjuvant PF03512676, a Toll-like receptor 9 agonist, which augments cellular im
25 otein formulated in Toll-like receptor 7 and Toll-like receptor 9 agonists, and DNA priming followed
26 naive B cells via B-cell receptor (BCR) and Toll-like receptor 9, along with T-cell help, failed to
28 naling influences the liver DC expression of toll-like receptor 9 and IL-1 receptor associated kinase
29 s for innate antiviral responses, triggering Toll-like receptor 9 and inducing alpha/beta interferon
32 ral killer cell dependent and ineffective in Toll-like Receptor 9(-/-) and interleukin 6(-/-) mice, w
33 as partially CD4 dependent and functional in Toll-like Receptor 9(-/-) and interleukin 6(-/-) mice.
34 bacteria, T-cell-independent activation via Toll-like receptor 9, and differentiation into non-NTHi-
35 , Henault et al. show that Fcgamma-receptor, Toll-like receptor 9, and LC3 conspire to mold phagosome
36 phosphate-guanosine (CpG) DNA motifs through toll-like receptor 9, and we found that the synthetic Cp
37 somal acidification inhibitor chloroquine, a Toll-like receptor 9 antagonist inhibitory CpG DNA, or o
38 asmacytoid dendritic cells via activation of Toll-like receptor 9, but independently of the IL-26 rec
39 Upon investigating the mechanism by which toll-like receptor 9 deficiency prevents the failure of
42 , it was found that neutrophils derived from toll-like receptor 9--deficient mice with cecal ligation
47 e score (2-4) on day 1 had higher neutrophil Toll-like receptor 9 expression, arterial ammonia concen
48 sociated with mortality in patients with low toll-like receptor-9 expression (odds ratio, 1.1; p = 0.
52 e liver failure plasma and endogenous DNA on Toll-like receptors-9 expression, healthy neutrophils we
53 he toll-like receptor 4 gene (TLR4), and the toll-like receptor 9 gene (TLR9) in a cohort of 336 reci
56 -kappaB-->ZEB1 signaling represses the TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattrac
58 Toll-like receptor 9 with a telomere-derived Toll-like receptor 9 inhibitory oligonucleotide or trans
60 or 9 inhibitory oligonucleotide or transient Toll-like receptor 9 knockdown with small interfering RN
61 and defective responses to stimulation with Toll-like receptor 9 ligand (TLR9-L), regardless of the
62 our previous finding that the combination of Toll-like receptor 9 ligand CpG and interleukin (IL)-4 s
63 or to treatment with poly-ICLC or a specific Toll-like receptor 9 ligand, CpG oligodeoxynucleotides.
65 or prostate cancer cells stably adorned with Toll-like receptor-9 ligand-loaded particles using strep
66 tion of IL-8 was observed using conventional Toll-like receptor 9 ligands (CpG oligonucleotides), alt
68 adation after pressure overload can activate Toll-like receptor-9 mediated innate immunity, causing m
69 in CLL by suppressing BCR, CD49d, CD40, and Toll-like receptor 9-mediated AKT activation in an integ
71 pite functionally intact IL-21 receptor- and Toll-like receptor 9-mediated signal transducer and acti
73 eatment inhibited Toll-like receptor 4, MD2, Toll-like receptor 9, myeloid differentiation factor 88,
75 at stimulate innate immune responses through Toll-like receptor-9 on B cells and plasmacytoid dendrit
77 e in vitro stimulation of B-cell receptor or Toll-like receptor 9 pathways were reduced in patients w
80 dings demonstrate that bacterial DNA through Toll-like receptor 9 shifted the balance of tissue facto
81 d that only patients with high expression of toll-like receptor-9 showed an increased risk associated
83 l and that TRAF6 is a diverging point in the Toll-like receptor 9-signaling pathway for CpG DNA-media
84 h it could be demonstrated that parts of the Toll-like receptor 9-signaling pathway were functional,
86 recognition threshold for the activation of Toll-like receptor 9, the principal DNA-recognizing tran
87 cterial DNA enhance immune responses through Toll-like receptor 9 (TLR-9) and may also demonstrate ad
88 ion in human monocytic cells (THP-1) through Toll-like receptor 9 (TLR-9) and nuclear factor-kappaB s
89 oduction by human PDCs through engagement of Toll-like receptor 9 (TLR-9) and TLR-7, respectively, wi
91 rich in unmethylated CG motifs (CpGs) engage Toll-Like Receptor 9 (TLR-9) in endosomes and are well d
93 pression of bacterial DNA sensors, including Toll-like receptor 9 (TLR-9), DNA-dependent activator of
94 d CpG-containing DNA, which is recognized by Toll-like receptor 9 (TLR-9), has been strongly implicat
95 ization to early endosomes and signaling via Toll-like receptor 9 (TLR-9), it can result in product p
97 , and the capacity to respond to ligands for Toll-like receptor 9 (TLR-9; CpG ODN 1668), but not to l
98 focuses on sublingual immunotherapy (SLIT), toll-like receptor-9 (TLR-9) vaccines using cytosine pho
100 ich was prevented by CXCR2-FPR1 blockage and Toll-like receptor 9 (TLR9) absence (TLR9(-/-) mice).
101 ication (FLT3-ITD)-negative AML, BTK couples Toll-like receptor 9 (TLR9) activation to nuclear factor
102 re cultured with CD40 ligand (CD40L) and the Toll-like receptor 9 (TLR9) agonist cytidine-phosphate-g
103 Previous clinical studies suggest that the Toll-Like Receptor 9 (TLR9) agonist DIMS0150 not only in
104 lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic ant
105 a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and i
106 uanidine (CpG) oligodeoxynucleotide (ODN), a toll-like receptor 9 (TLR9) agonist, confers protection
107 thesized that a single drug molecule-a novel Toll-like receptor 9 (TLR9) agonist, MGN1703-could funct
110 his study we observed that administration of Toll-like receptor 9 (TLR9) agonists suppressed the seve
112 ly, we identify parasite DNA-sensing through Toll-like receptor 9 (TLR9) along with inflammatory cyto
114 okines via a cooperative interaction between Toll-like receptor 9 (TLR9) and FcgammaRIIa (CD32).
116 nition of adenovirus by pDCs was mediated by Toll-like receptor 9 (TLR9) and was dependent on MyD88,
117 70S6K1 and p70S6K2, during pDC activation by Toll-like receptor 9 (TLR9) blocked the interaction of T
122 clude the BMAL1:CLOCK heterodimer regulating toll-like receptor 9 (TLR9) expression and repressing ex
124 l early in clinical development, agonists of Toll-like receptor 9 (TLR9) have demonstrated potential
126 engagement of the B cell receptor (BCR) and Toll-like receptor 9 (TLR9) in response to DNA-containin
127 -mobility group B1 (HMGB1) protein activates Toll-like receptor 9 (TLR9) in the adipose-recruited pDC
128 a key role in recognition, as highlighted by Toll-like receptor 9 (TLR9) in the endosomal compartment
133 that following challenge with A. fumigatus, Toll-like receptor 9 (TLR9) knockout mice survived longe
135 raft-versus-host disease (GVHD) lethality by Toll-like receptor 9 (TLR9) ligation of host antigen-pre
142 d-induced IL-1beta release is dependent upon Toll-like receptor 9 (TLR9) sensing of the Ad5 double-st
144 ke into endosomes, the rate-limiting step of Toll-like receptor 9 (TLR9) signaling, is critical in el
146 responsiveness of paired lung fibroblasts to Toll-like receptor 9 (TLR9) stimulation by CpG-oligodeox
147 ning oligodeoxynucleotides (CpG ODNs) act on Toll-like receptor 9 (TLR9) that is expressed on B cells
149 tion and immunoglobulin production driven by Toll-like receptor 9 (TLR9) were considerably lower in D
150 stimulated the innate immune system via the Toll-like receptor 9 (TLR9) with cytosine-guanosine-cont
151 act with ACs, results from the engagement of Toll-like receptor 9 (TLR9) within the B cell after reco
154 ear factor-kappaB transcription factor RelB, toll-like receptor 9 (TLR9), and interferon consensus se
155 robial DNA to its cognate receptors, such as Toll-like receptor 9 (TLR9), can trigger inflammation.
156 hed oligodeoxynucleotide, an agonist for the toll-like receptor 9 (TLR9), induces the activation of n
158 recruitment domain [ASC], NLRP3, caspase-1), Toll-like receptor 9 (TLR9), or the purinergic receptor
159 tic DNA rich in CpG dinucleotides stimulates Toll-like receptor 9 (TLR9), whereas DNA lacking CpG eit
161 ell-receptor signaling induces the fusion of Toll-like receptor 9 (TLR9)-containing endosomes with in
163 ow that Opn deficiency substantially reduced Toll-like receptor 9 (TLR9)-dependent IFN-alpha response
166 FcvarepsilonRI receptor for IgE, followed by Toll-like receptor 9 (TLR9)-mediated sensing of DNA in p
167 intravenous DNASE1 injection or ablation of Toll-like receptor 9 (TLR9)-mediated sensing significant
168 227A signaling and B-cell receptor (BCR)- or Toll-like receptor 9 (TLR9)-mediated signaling was also
170 trategy based on targeted Stat3 silencing in Toll-like receptor 9 (TLR9)-positive hematopoietic cells
194 stem and microglia/macrophage activation via Toll-like receptor 9 using CpG (cytosine-phosphate-guani
196 th CRS, although a 50% reduced expression of Toll-like receptor 9 was reported in patients with recal
198 -containing oligodeoxynucleotides binding to toll-like receptor 9, with enhanced IFN-alpha transcript
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。